Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 9/20 | 0.63 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.63 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31193414 | 0.90 | ERAP2 (0.50) | FURINPCSK6NPY1RNPY2RNPY4R | |
| SCHEMBL29494597 | 0.89 | NPY1R (0.66) | FURINPCSK6NPY1RNPY2RNPY4R | |
| SCHEMBL31151632 | 0.87 | FURIN (0.54) | FURINPCSK6NPY1RNPY2RNPY4R | |
| SCHEMBL31151774 | 0.87 | NPY1R (0.72) | FURINPCSK6NPY1RNPY2RNPY4R | |
| SCHEMBL29706243 | 0.87 | ERAP2 (0.53) | FURINPCSK6 | |
| SCHEMBL31151641 | 0.85 | NPY1R (0.69) | NPY1RNPY2RNPY4RSMN1; SMN2 | |
| SCHEMBL29396192 | 0.84 | NPY1R (0.59) | NPY1RNPY2RNPY4RCTSLCTSB | |
| SCHEMBL29666891 | 0.84 | ERAP2 (0.54) | NPY1RNPY2RNPY4R | |
| SCHEMBL29625510 | 0.84 | NTSR2 (0.48) | FURINPCSK6CTSBCTSKCCNA2 | |
| SCHEMBL29591847 | 0.84 | ERAP2 (0.48) | FURINPCSK6NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713019-A2 | CPG CONJUGATES AND METHODS OF USE | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4288780-B1 | METHODS FOR CANCER DETECTION | DISRUPTIVE TECH ADVANCES IN LIFE SCIENCE S R L SOCIETA BENEFIT IN FORMA ABBREVIATA D TAILS S R L SB (IT) | 2025-06-04 | — | — | EP | claimed |
| WO-2025109111-A1 | IMMUNE CELL ACTIVATING MULTIMERS | IMMUDEX APS (DK) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119367321-A | Recombinant fusion protein-polyester nano drug delivery system and preparation method and application thereof | 华南理工大学 | 2025-01-28 | — | — | CN | claimed |
| CN-119173528-A | Bispecific antibodies against CD277 and tumor antigens | 勃林格殷格翰国际公司 | 2024-12-20 | — | — | CN | claimed |
| WO-2024238677-A2 | CPG CONJUGATES AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-11-21 | — | — | WO | claimed |
| CN-118786207-A | Modified cells and uses thereof | 西湖生物医药科技(上海)有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118527647-A | Near infrared light response type nano material and preparation method and application thereof | 广西医科大学 | 2024-08-23 | — | — | CN | claimed |
| CN-113278061-B | Method for preparing cable Ma Lutai by biochemical method | 南京林业大学 | 2024-04-09 | — | — | CN | claimed |
| CN-116437949-A | Antigen binding domains with reduced shear rate | 安进公司 | 2023-07-14 | — | — | CN | claimed |
| EP-4192481-A1 | MATERIALS AND METHODS FOR PRODUCING BIOENGINEERED VIRUS SPECIFIC LYMPHOCYTES | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| CN-115819542-A | Screening and application of echinococcus granulosus recombinant antigen P29 dominant epitope peptide | 宁夏医科大学 | 2023-03-21 | — | — | CN | claimed |
| WO-2023036215-A1 | BISPECIFIC ANTIGEN BINDING MOLECULE AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-03-16 | — | — | WO | claimed |
| WO-2022246250-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS | WASHINGTON UNIVERSITY (US) | 2022-11-24 | — | — | WO | claimed |
| CN-217773312-U | Peptide fragment desalting device in proteomics | 杭州聚米生物科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | MONASH UNIVERSITY (AU) | 2022-09-20 | — | — | US | claimed |
| EP-4037709-A1 | KNOTTIN-IMMUNOSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-08-10 | — | — | EP | claimed |
| WO-2022026906-A9 | LYSOSOMAL TARGETING MOLECULES COMPRISING KNOTTIN PEPTIDES AND RELATED COMPOSITIONS AND METHODS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| EP-3972647-A1 | DRUG CONJUGATES AND METHODS OF USING SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-03-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | LNPEP, TLR9, LPXN | FURIN 375/4885PCSK6 362/4885NPY1R 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.